Abstract:To retrospectively analyze the effect of postoperative intensity-modulated radiation therapy (IMRT) on the recurrence and survival in patients with lymph node positive or Stage III thoracic esophageal squamous cell carcinoma (TESCC), and evaluate the role of postoperative IMRT in the TESCC therapy. From January 2004 to June 2009, 535 patients with TESCC underwent radical resection with or without postoperative IMRT were eligible for analysis. Inclusion criteria: (1) having undergone radical resection (R0); (2) a diagnosis of squamous cell carcinoma confirmed by pathological studies; (3) Karnofsky performance status scale ≥70; (4) Preoperative neoadjuvant therapy was not proceeded; (5) postoperative pathologic stage was IIb or III. According to UICC02 stage classification, 122 patients were stage IIb and 413 patients were stage III. Patients were grouped to surgery alone (n = 345) and surgery plus postoperative IMRT (n = 190). The median total dose in postoperative IMRT was 60 Gy. The Kaplan-Meier method was used to calculate the survival rates, and the log-rank test was used for univariate analysis. The chi-square test was used to analyze the sites of failure of esophageal cancer with different treatments. The 1-, 3-, and 5-year overall survival (OS) and disease-free survival (DFS) for all the patients were 79.5%, 42.7%, 32.8%, and 67.2%, 38.0%, 32.5%, and the median OS and DFS were 28.6 months and 21.5 months, respectively. For patients with stage IIb and stage III, the 5-year OS rates were 45.3% and 29.2%, respectively (p = 0.001). The 5-year OS in the patients with lymph node positivity was 28.5% in the group receiving surgery alone and 38.9% in the group undergoing surgery plus postoperative IMRT (p = 0.000). The 5-year OS rates in patients with stage III was 24.3% in the surgery group and 38.0% in the surgery plus postoperative IMRT group, respectively (p = 0.001). Use of postoperative IMRT resulted in significant decrease in intrathoracic recurrence from 33.6% to 13.3% (p = 0.000) as well as supraclavicular recurrence from 13.4% to 6.1% (p = 0.012), Similarly, use of postoperative IMRT obviously delayed the median local recurrence from 10.7 months to 20.7 months and the median system metastases from 8.8 months to 14.5 months. While systemic metastases increased from 21.6% to 30.4% (p = 0.032) by postoperative IMRT treatment. Postoperative IMRT reduced local recurrence and improved survival for patients with lymph node positive or stage III TESCC, which would provide rationale in establishing patient selection criteria for the postoperative IMRT for TESCC after surgery.

Reduced frequency and severity of radiation esophagitis without marginal failure risk by contralateral esophagus sparing IMRT in stage III non-small cell lung cancer patients undergoing definitive concurrent chemoradiotherapy

Postoperative Intensity Modulated Radiation Therapy Improved Survival of Lymph Node-Positive or Stage III Squamous Cell Carcinoma Esophagus

The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinoma

Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity

Long-Term Outcomes of Three-Dimensional Conformal Radiation Therapy Without Chemotherapy for Esophageal Squamous Cell Carcinoma: A Final Report of a Phase 2 Study

High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial

Risk Factors for Acute Esophagitis in Non–small-Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Three-Dimensional Conformal Radiotherapy

FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses

A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma

Long Term Results of Different Radiotherapy Techniques and Fractions for Esophageal Squamous Cell Carcinoma

Different Radiation Treatment in Esophageal Carcinoma: a Clinical Comparative Study.

Efficacy and Safety of Definitive Chemoradiotherapy with or Without Induction Immune Checkpoint Inhibitors in Patients with Stage III Non-Small Cell Lung Cancer

Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial

Efficacy and Safety of Radiotherapy/chemoradiotherapy Combined with Immune Checkpoint Inhibitors for Locally Advanced Stages of Esophageal Cancer: A Systematic Review and Meta-Analysis

Feasibility and Efficacy of Helical Intensity-Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in Comparison with Conventionally Fractionated 3D-CRT.

Do higher radiation doses improve survival for cervical esophageal squamous cell cancer patients treated with definitive chemoradiotherapy using intensity-modulated radiotherapy? A propensity-score matched analysis

Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity

Less Irradiation to Lymphocyte-Related Organs Reduced the Risk of G4 Lymphopenia in Esophageal Cancer: Re-Analysis of Prospective Trials

Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer

Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial